Margaret Duffy, Co-Founder and Chief Scientific Officer of Theolytics, shared a post by Theolytics, adding:
“We are thrilled to be selected for an €8M Grant Award from Horizon Europe to support the advancement of our oncolytic immunotherapy THEO-260 to Ph2a trials. We are working with top class clinical and translational centres to develop this novel modality for advanced cancer patients, and this grant further bolsters our efforts!”
Quoting Theolytics‘s post:
“Theolytics has been awarded €8 million in non-dilutive Horizon Europe 2025 funding to support our Phase 2a expansion of OCTOPOD-IV evaluating THEO-260 in platinum-resistant ovarian cancer.
This highly competitive award recognises our differentiated oncolytic and CAF-lytic approach, and the strength of our international clinical partnerships.
We look forward to advancing this important programme for patients with significant unmet need.
Read the full press release.”
Other articles on OncoDaily.